Vaccine Therapy in Treating Patients With Malignant Glioma

Inclusion Criteria: * Histologically confirmed diagnosis of 1 of the following malignant gliomas: * Anaplastic astrocytoma * Glioblastoma multiforme * Oligodendroglioma * Oligoastrocytoma * WHO grade III or IV disease * Newly diagnosed or recurrent disease * Bidimensionally measurable disease by contrast-enhancing MRI * Surgically accessible tumor for which resection is indicated * Previously treated with or planning to undergo treatment with conventional external beam radiotherapy * HLA-A\*201 positive * Karnofsky performance status 60-100% * Life expectancy ≥ 8 weeks * Hemoglobin ≥ 10 g/dL * Absolute granulocyte count ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * SGOT and SGPT ≤ 2 times normal * Alkaline phosphatase ≤ 2 times normal * Bilirubin ≤ 1.5 mg/dL * BUN ≤ 1.5 times normal OR creatinine ≤ 1.5 times normal * Negative pregnancy test * Fertile patients must use effective contraception * Hepatitis B negative * Hepatitis C negative * HIV negative * Syphilis serology negative * Afebrile Exclusion Criteria: * active infection * immunodeficiency * autoimmune disease that may be exacerbated by immunotherapy, including any of the following: * Rheumatoid arthritis * Systemic lupus erythematosus * Vasculitis * Polymyositis-dermatomyositis * Scleroderma * Multiple sclerosis * Juvenile-onset insulin-dependent diabetes * allergy to study agents * underlying condition that would contraindicate study therapy * concurrent severe or unstable medical condition that would preclude giving informed consent * psychiatric condition that would preclude study participation or giving informed consent * other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, localized prostate cancer, or carcinoma in situ of the cervix * prior chemotherapy (6 weeks for nitrosoureas) within last 4 weeks of starting treatment * concurrent corticosteroids within 2 weeks prior to treatment * radiotherapy within 2 weeks prior to treatment * systemic antibiotics within 72 hours prior to treatment * prior organ allograft * antihistamine therapy within 5 days before or after administration of study vaccine * chemotherapy during and for 4 weeks after administration of study vaccine * adjuvant therapy during and for 4 weeks after administration of study vaccine * other concurrent investigational agents